Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.72 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.55 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 3/20 | 0.41 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.41 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986303 | 1.00 | PGR (0.72) | PGRCDYL2CDYLTP53MAPT | |
| SCHEMBL25767723 | 0.87 | PGR (0.63) | PGRCDYL2CDYLHTR7CACNB4 | |
| SCHEMBL23835763 | 0.87 | PGR (0.63) | PGRCDYL2CDYLHTR7CACNB4 | |
| SCHEMBL5223844 | 0.84 | PGR (1.00) | PGRCDYL2CDYLHTR7 | |
| SCHEMBL2988866 | 0.81 | PGR (0.57) | PGRTP53MAPTPOLBLMNA | |
| SCHEMBL24019919 | 0.81 | PGR (0.57) | PGRTP53MAPTPOLBLMNA | |
| SCHEMBL16977576 | 0.81 | IDO1 (0.62) | PGRCDYL2CDYLTP53MAPT | |
| SCHEMBL8303268 | 0.81 | PGR (0.53) | PGRCDYL2CDYLMEN1KMT2A | |
| SCHEMBL2989569 | 0.80 | TP53 (0.62) | PGRTP53MAPTPOLBLMNA | |
| SCHEMBL2320598 | 0.80 | PGR (0.56) | PGRCDYL2CDYLTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402896-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSV, CTRL, CTSL | PGR 3775/4885CDYL2 2691/4885CDYL 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.